ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0021

Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned

Dominique Kinnett-Hopkins1, Linda Ehrlich-Jones2, Holly Milaeger3, Alanna Kenney3, Lorena Rosiles3 and Rosalind Ramsey-Goldman4, 1Northwestern University, Chicago, IL, 2Shirley Ryan AbilityLab, Chicago, 3Northwestern University, Chicago, 4Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: ACR Convergence 2020

Keywords: COVID-19, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended a moratorium on conducting in-person research and study enrollment until protocol changes to protect patient safety were implemented and approved. We turned the guidance provided by the Institutional Review Board (IRB) into actionable items without compromising the integrity of the primary, secondary, and exploratory outcomes of the study. The purpose of this project is to detail the modifications made to the Lupus Intervention Fatigue Trial (LIFT) and to summarize the lessons learned to meet the varied challenges created by the highly transmissible virus.

Methods: The research team evaluated current study protocols to determine which components required modification. The research team determined that the following protocols required modifications: 1) the intervention that included four individual coaching sessions and 2) four, two-hour, in-person assessments, including a physician exam, blood draws, and urine samples along with online patient-reported outcomes (PROs) at a University Medical Center Research Unit. The team made modifications that would allow for all interventions and assessments to be safely conducted remotely without compromising the integrity of the study aims.

Results: The intervention components were revised immediately to convert all individual coaching sessions to remote sessions. Next, we reviewed all study assessments and modifications were made to electronically consent participants, provide links for completion of online PROs, and perform telemedicine visits for the physician assessment. Collection of safety labs presented the biggest challenge since this required an in-person visit at a laboratory and we elected to delay this up to one month after the physician assessment, or used standard of care test results if they were done within a month of the physician assessment. We also offered the option of not doing the lab tests. With these modifications, we were able to complete all follow-up visits and no patients dropped out of the study. We were not able to collect the protocol extra blood for future research testing and some patients could not measure their vital signs at home.

Conclusion: The LIFT study was severely impacted by COVID-19. We provide insight into how our study protocol was modified without compromising the integrity of the primary, secondary, and exploratory outcomes of the study. The modifications utilized by the LIFT study and lessons learned while revising the LIFT protocols resulted in efficiencies that will be included in a revised protocol and will foster additional ideas to overcome the challenges in areas where we missed data collection and may serve as a useful example for other behavioral interventions to adapt their research studies given COVID-19 restrictions.


Disclosure: D. Kinnett-Hopkins, None; L. Ehrlich-Jones, Zimmer Biomet, 8; H. Milaeger, None; A. Kenney, None; L. Rosiles, None; R. Ramsey-Goldman, None.

To cite this abstract in AMA style:

Kinnett-Hopkins D, Ehrlich-Jones L, Milaeger H, Kenney A, Rosiles L, Ramsey-Goldman R. Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prioritizing-patient-safety-while-maintaining-study-integrity-during-covid-19-lupus-intervention-fatigue-trial-modifications-and-lessons-learned/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prioritizing-patient-safety-while-maintaining-study-integrity-during-covid-19-lupus-intervention-fatigue-trial-modifications-and-lessons-learned/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology